{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:14Z","timestamp":1793946554313,"version":"4.8.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2314-B-182-070-MY3"],"award-info":[{"award-number":["112-2314-B-182-070-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eclinm.2026.104026","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:52:11Z","timestamp":1781859131000},"page":"104026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reassessing the risk-modifying effects of novel antidiabetic agents on asthma\u2013COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials"],"prefix":"10.1016","volume":"97","author":[{"given":"Bing-Yan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Ming","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Te","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Jy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Pin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow-Ling","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Syuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-2502","authenticated-orcid":false,"given":"Kuan-Pin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mein-Woei","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7800","authenticated-orcid":false,"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104026_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/DMSO.S456336","article-title":"Effect of semaglutide and empagliflozin on pulmonary structure and proteomics in Obese mice","volume":"17","author":"Yang","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14728222.2022.2077723","article-title":"Dapagliflozin mitigates ovalbumin-prompted airway inflammatory-oxidative successions and associated bronchospasm in a rat model of allergic asthma","volume":"26","author":"Tabaa","year":"2022","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/ecp.13.2","article-title":"The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations","volume":"6","author":"Louie","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib4","first-page":"721","article-title":"Opportunities and challenges of clinical research in the big-data era: from RCT to BCT","volume":"5","author":"Wang","year":"2013","journal-title":"J Thorac Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib5","first-page":"1659","article-title":"Big data and clinical research: perspective from a clinician","volume":"6","author":"Zhang","year":"2014","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib6","first-page":"607","article-title":"The association between GLP-1 receptor-based agonists and the incidence of asthma in patients with type 2 diabetes and\/or obesity: a meta-analysis","volume":"37","author":"Zhang","year":"2024","journal-title":"Biomed Environ Sci"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.eclinm.2026.104026_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.743807","article-title":"Comprehensive analysis of adverse events associated with SGLT2is: a meta-analysis involving nine large randomized trials","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00228-024-03631-7","article-title":"The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs","volume":"80","author":"Wang","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2026.104026_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.724405","article-title":"Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials","volume":"12","author":"Yin","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9994","key":"10.1016\/j.eclinm.2026.104026_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","article-title":"Network meta-analysis: a norm for comparative effectiveness?","volume":"386","author":"Higgins","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12916-025-04018-w","article-title":"The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis","volume":"23","author":"Tseng","year":"2025","journal-title":"BMC Med"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104026_bib13","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.3390\/ijms26178202","article-title":"The preventive effects of GLP-1 receptor agonists and SGLT2 inhibitors on cancer metastasis: a network meta-analysis of 67 randomized controlled trials","volume":"26","author":"Hsu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.104026_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/JS9.0000000000003450","article-title":"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials","volume":"112","author":"Hung","year":"2026","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-025-01750-x","article-title":"The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","volume":"18","author":"Tseng","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biom15111622","article-title":"Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: preliminary findings from a pilot network meta-analysis","volume":"15","author":"Lin","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ph18050735","article-title":"Risk of hearing loss in patients treated with Exendin-4 derivatives: a network meta-analysis of glucagon-like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"18","author":"Chen","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eclinm.2026.104026_bib18","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Chapter 19: adverse effects","author":"Peryer","year":"2023"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13040677","article-title":"Asthma-COPD overlap in clinical practice (ACO_CP 2023): toward precision medicine","volume":"13","author":"Alsayed","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MCP.0000000000000649","article-title":"Asthma-COPD overlap: review of diagnosis and management","volume":"26","author":"Venkata","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1183\/13993003.00436-2016","article-title":"What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion","volume":"48","author":"Sin","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5227","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"41","key":"10.1016\/j.eclinm.2026.104026_bib23","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.2174\/1381612822666160906162441","article-title":"Asthma COPD overlap syndrome: an approach to A real -World endotype in obstructive lung disease?","volume":"22","author":"Laucho-Contreras","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12874-022-01541-9","article-title":"Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews","volume":"22","author":"Salika","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2026.104026_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"STATA J"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0272989X14545789","article-title":"Use of generalized linear mixed models for network meta-analysis","volume":"34","author":"Tu","year":"2014","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-Week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahren","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.eclinm.2026.104026_bib29","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104026_bib30","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/CIRCULATIONAHA.121.054669","article-title":"Kidney function after initiation and discontinuation of empagliflozin in patients with heart failure with and without type 2 diabetes: insights from the EMPERIAL trials","volume":"144","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"issue":"10403","key":"10.1016\/j.eclinm.2026.104026_bib32","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104026_bib34","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/dom.15079","article-title":"Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: the AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/1753-0407.12456","article-title":"Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin","volume":"9","author":"Ba","year":"2017","journal-title":"J Diabetes"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib36","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1185\/03007995.2011.568059","article-title":"Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Barzilai","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"9683","key":"10.1016\/j.eclinm.2026.104026_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104026_bib40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib41","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00125-013-2905-1","volume":"56","author":"Charbonnel","year":"2013","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib42","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"10278","key":"10.1016\/j.eclinm.2026.104026_bib44","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as Add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib47","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/dom.12643","article-title":"Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus","volume":"18","author":"Del Prato","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10313","key":"10.1016\/j.eclinm.2026.104026_bib49","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104026_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012349","article-title":"Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials","volume":"17","author":"Docherty","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Frias","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib52","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.2337\/dc21-2656","article-title":"Efficacy and safety of once-weekly efpeglenatide monotherapy versus placebo in type 2 diabetes: the AMPLITUDE-M randomized controlled trial","volume":"45","author":"Frias","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dom.13631","article-title":"Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial","volume":"21","author":"Gallo","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib55","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc10-1900","article-title":"Exenatide twice daily versus premixed insulin aspart 70\/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia","volume":"34","author":"Gallwitz","year":"2011","journal-title":"Diabetes Care"},{"issue":"9833","key":"10.1016\/j.eclinm.2026.104026_bib56","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"issue":"9840","key":"10.1016\/j.eclinm.2026.104026_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-017-0593-8","article-title":"A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus","volume":"16","author":"Gantz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"10193","key":"10.1016\/j.eclinm.2026.104026_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104026_bib60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib61","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib62","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/ijcp.12119","article-title":"Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial","volume":"67","author":"Goke","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib63","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib64","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104026_bib66","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","article-title":"Initial combination of empagliflozin and metformin in patients with type 2 diabetes","volume":"39","author":"Hadjadj","year":"2016","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104026_bib67","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.eclinm.2026.104026_bib68","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/1479164111404575","article-title":"Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus","volume":"8","author":"Hollander","year":"2011","journal-title":"Diab Vasc Dis Res"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104026_bib70","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104026_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.diabres.2017.06.013","article-title":"Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy","volume":"131","author":"Home","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib74","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib75","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib76","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdi.12092","article-title":"Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus","volume":"4","author":"Kadowaki","year":"2013","journal-title":"J Diabetes Investig"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/dom.12235","article-title":"Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension","volume":"16","author":"Kadowaki","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib78","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib79","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib80","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib81","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2337\/dc14-1684","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial","volume":"38","author":"Laakso","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib82","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib83","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/dom.13829","article-title":"Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial","volume":"21","author":"Ledesma","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.eclinm.2026.104026_bib84","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib85","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2026.104026_bib86","author":"Lock"},{"issue":"10300","key":"10.1016\/j.eclinm.2026.104026_bib87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib88","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.eclinm.2026.104026_bib89","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib90","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib91","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","article-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin Add-on to saxagliptin plus metformin in type 2 diabetes","volume":"38","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib92","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13300-015-0105-3","article-title":"A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine","volume":"6","author":"Mathieu","year":"2015","journal-title":"Diabetes Ther"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib93","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.2337\/dc15-0811","article-title":"Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care"},{"issue":"10208","key":"10.1016\/j.eclinm.2026.104026_bib94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.eclinm.2026.104026_bib95","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib96","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-Minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.eclinm.2026.104026_bib97","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib98","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40261-016-0438-3","article-title":"Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis","volume":"36","author":"Mellander","year":"2016","journal-title":"Clin Drug Invest"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13811","article-title":"Association of appendicular skeletal muscle mass index and insulin resistance with mortality in multi-nationwide cohorts","volume":"16","author":"Moon","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib100","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib101","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib102","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib103","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10148","key":"10.1016\/j.eclinm.2026.104026_bib104","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104026_bib105","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib107","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/dmrr.1306","article-title":"Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"28","author":"Pan","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"24","key":"10.1016\/j.eclinm.2026.104026_bib108","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.eclinm.2026.104026_bib110","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104026_bib113","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib114","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2008.01016.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy","volume":"11","author":"Pratley","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib116","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1463-1326.2011.01390.x","article-title":"The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus","volume":"13","author":"Reasner","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib117","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2026.104026_bib118","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.eclinm.2026.104026_bib120","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104026_bib121","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"10401","key":"10.1016\/j.eclinm.2026.104026_bib122","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib123","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/dme.12267","article-title":"Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes","volume":"30","author":"Rosenstock","year":"2013","journal-title":"Diabet Med"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib124","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104026_bib125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib126","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104026_bib127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/dom.12461","article-title":"Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)","volume":"17","author":"Schernthaner","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.eclinm.2026.104026_bib128","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib129","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/dc15-0109","article-title":"Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes","volume":"38","author":"Sheu","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib131","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib132","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study","volume":"30","author":"Stenlof","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eclinm.2026.104026_bib133","author":"SURMOUNT"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib134","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104026_bib135","author":"Trials"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib136","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc21-2034","article-title":"Safety of empagliflozin in patients with type 2 diabetes and chronic kidney disease: pooled analysis of placebo-controlled clinical trials","volume":"45","author":"Tuttle","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsboll","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104026_bib138","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib139","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib140","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","article-title":"Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial","volume":"67","author":"Wang","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.eclinm.2026.104026_bib141","author":"Wason"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104026_bib142","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib143","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00125-014-3360-3","article-title":"HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea","volume":"57","author":"Weissman","year":"2014","journal-title":"Diabetologia"},{"issue":"14","key":"10.1016\/j.eclinm.2026.104026_bib144","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104026_bib146","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib147","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104026_bib148","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104026_bib149","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2337\/dc12-2718","article-title":"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a >\/=52-week randomized, double-blind study","volume":"36","author":"Yki-Jarvinen","year":"2013","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.eclinm.2026.104026_bib150","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104026_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109080","article-title":"Association between novel glucose-lowering drugs and risk of asthma: a network meta-analysis of cardiorenal outcome trials","volume":"183","author":"Wang","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eclinm.2026.104026_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/09603271221125931","article-title":"Semaglutide ameliorates lipopolysaccharide-induced acute lung injury through inhibiting HDAC5-mediated activation of NF-kappaB signaling pathway","volume":"41","author":"Jiang","year":"2022","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib153","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.alit.2018.01.001","article-title":"Asthma and COPD overlap pathophysiology of ACO","volume":"67","author":"Hikichi","year":"2018","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104026_bib154","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5455\/msm.2012.24.100-105","article-title":"Asthma and Chronic Obstructive Pulmonary Disease (COPD) - differences and similarities","volume":"24","author":"Cukic","year":"2012","journal-title":"Mater Sociomed"},{"key":"10.1016\/j.eclinm.2026.104026_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109631","article-title":"Sodium glucose cotransporter2 inhibitor-possible treatment for patients with diabetes, pulmonary disease and CO(2) retention","volume":"139","author":"Brikman","year":"2020","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104026_bib156","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/0976-500X.85934","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus","volume":"2","author":"Dave","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104026_bib157","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaip.2014.09.011","article-title":"Infection-related asthma","volume":"2","author":"Darveaux","year":"2014","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:49:55Z","timestamp":1793944195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":157,"alternative-id":["S2589537026002798"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104026","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the risk-modifying effects of novel antidiabetic agents on asthma\u2013COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104026"}}